Dapa T1DM Positive CHMP Opinion for AZ

AZ received a positive CHMP opinion for dapagliflozin in T1DM and confirmed that dapa T1DM is under review by FDA. The company will likely discuss the positive CHMP opinion and US filing during its Q4 ’18 earnings call on February 14. Below, FENIX provides thoughts on a dapa T1DM indication in the context of the recent sotagliflozin FDA adcom.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.